April 16, 2014 – The U.S. Food and Drug Administration (FDA)  yesterday  approved Tanzeum (albiglutide) subcutaneous injection to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes. Type 2 diabetes affects approximately 24 million people …

FDA approves Albiglutide [Tanzeum] to treat type 2 diabetes Read more »

May 09, 2013 – We have just stumbled upon a recent press release to the public by the American Food and Drug Administration (FDA) on a looming drug safety problem of incretin mimetic drugs related to the pancreas. Find here …

Incretin Mimetic Drugs for Type 2 Diabetes: Early Communication – Reports of Possible Increased Risk of Pancreatitis and Pre-cancerous Findings of the Pancreas Read more »

October 14, 2009 – On October 5, 2009, drug maker Bristol-Myers Squibb Co. announced that its new diabetes drug, Saxagliptin [Onglyza], has been approved for sale in the European Union’s (EU) 27 countries. Saxagliptin [Onglyza] is the first diabetes drug …

Bristol-Myers gets approval for its diabetes drug Saxagliptin [Onglyza] in the European Union (EU) Read more »